Abstract
Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic medications. Canagliflozin was the first drug approved in this group in 2013 and subsequently dapagliflozin was approved in January 2014 and empagliflozin was approved in August 2014. Preclinical studies have demonstrated safety, tolerability, and efficacy in terms of glycemic control and HbA1c level in type 2 diabetes mellitus (T2DM) patients in comparison to other anti-diabetic drugs. The U.S. Food and Drug Administration (FDA) recently released a warning that some of the patients who used SGLT2 inhibitors developed diabetic ketoacidosis (DKA). Empagliflozin has showed safety in type 2 diabetics with renal impairment. Each of these medications can be used as a single treatment or in combination with other anti-diabetic medications.
Keywords: Anti-hyperglycemic agents, dipeptidyl peptidase-4 inhibitors, fasting plasma glucose, sulphonylureas, sodium glucose co-transporter 2 inhibitors, SGLT2, type 1 diabetes mellitus, type 2 diabetes mellitus, urinary glucose excretion.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin
Volume: 13 Issue: 2
Author(s): Saad Hussain Syed, Sucheta Gosavi, Waseem Shami, Marco Bustamante, Zul Farah, Muhammad Teleb, Aamer Abbas, Sarmad Said and Debabrata Mukherjee
Affiliation:
Keywords: Anti-hyperglycemic agents, dipeptidyl peptidase-4 inhibitors, fasting plasma glucose, sulphonylureas, sodium glucose co-transporter 2 inhibitors, SGLT2, type 1 diabetes mellitus, type 2 diabetes mellitus, urinary glucose excretion.
Abstract: Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic medications. Canagliflozin was the first drug approved in this group in 2013 and subsequently dapagliflozin was approved in January 2014 and empagliflozin was approved in August 2014. Preclinical studies have demonstrated safety, tolerability, and efficacy in terms of glycemic control and HbA1c level in type 2 diabetes mellitus (T2DM) patients in comparison to other anti-diabetic drugs. The U.S. Food and Drug Administration (FDA) recently released a warning that some of the patients who used SGLT2 inhibitors developed diabetic ketoacidosis (DKA). Empagliflozin has showed safety in type 2 diabetics with renal impairment. Each of these medications can be used as a single treatment or in combination with other anti-diabetic medications.
Export Options
About this article
Cite this article as:
Syed Hussain Saad, Gosavi Sucheta, Shami Waseem, Bustamante Marco, Farah Zul, Teleb Muhammad, Abbas Aamer, Said Sarmad and Mukherjee Debabrata, A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin , Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (2) . https://dx.doi.org/10.2174/1871525714666151106121215
DOI https://dx.doi.org/10.2174/1871525714666151106121215 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brittle Type 1 Diabetes Mellitus
Current Medicinal Chemistry Antifungal Therapy Used in Central Nervous System Fungal Infections
Central Nervous System Agents in Medicinal Chemistry Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants
Endocrine, Metabolic & Immune Disorders - Drug Targets Halving Your Cake and Eating it, Too: A Case-based Discussion and Review of Metabolic Rehabilitation for Obese Adults with Diabetes
Current Diabetes Reviews Risks Associated with SGLT2 Inhibitors: An Overview
Current Drug Safety Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters Association Between Seizures and Diabetes Mellitus: A Comprehensive Review of Literature
Current Diabetes Reviews Activated T Lymphocytes in Type 2 Diabetes: Implications From in Vitro Studies
Current Drug Targets Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology Prevalence of Diabetes Ketoacidosis Rises and Still No Strict Treatment Adherence
Current Diabetes Reviews An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life
Current Diabetes Reviews Neonatal Diabetes: Applying Molecular Biology to Patient Care
Current Pediatric Reviews Surgical Complications of Hyperglycaemia
Current Diabetes Reviews Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice
Cardiovascular & Hematological Disorders-Drug Targets Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews Cystic Fibrosis Related Diabetes Mellitus - Diagnostic and Management Challenges
Current Diabetes Reviews Applications and Limitations of Genetically Modified Mouse Models in Drug Discovery and Development
Current Drug Metabolism GHB in Biological Specimens: Which Cut-off Levels Should be Taken into Consideration in Forensic Toxicological Investigation?
Recent Patents on Biotechnology Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued)